The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | RTOG 0617: radiation with concurrent chemotherapy and cetuximab in NSCLC
Stephen Chun, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the NRG Oncology-RTOG 0617 trial (NCT00533949), a study which compared standard-dose versus high-dose radiation with concurrent chemotherapy and determined the efficacy of cetuxumab for stage III non-small cell lung cancer (NSCLC). This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
